Xponance Inc. Acquires 190 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Xponance Inc. increased its holdings in Arcellx, Inc. (NASDAQ:ACLX) by 6.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,278 shares of the company’s stock after purchasing an additional 190 shares during the period. Xponance Inc.’s holdings in Arcellx were worth $215,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ACLX. FMR LLC increased its holdings in shares of Arcellx by 22.8% in the fourth quarter. FMR LLC now owns 7,956,633 shares of the company’s stock valued at $610,194,000 after purchasing an additional 1,477,360 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in Arcellx in the 4th quarter valued at $515,418,000. Vanguard Group Inc. grew its position in shares of Arcellx by 35.3% in the 4th quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company’s stock valued at $255,385,000 after acquiring an additional 867,996 shares during the period. RA Capital Management L.P. boosted its holdings in shares of Arcellx by 50.5% during the 4th quarter. RA Capital Management L.P. now owns 2,787,327 shares of the company’s stock worth $213,760,000 after buying an additional 935,848 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Arcellx by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,121,322 shares of the company’s stock worth $162,685,000 after purchasing an additional 220,711 shares in the last quarter. 96.03% of the stock is currently owned by institutional investors.

Insider Activity

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $67.36, for a total value of $101,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 4,500 shares of company stock worth $284,985. Insiders own 8.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ACLX shares. Scotiabank lowered their price objective on shares of Arcellx from $133.00 to $93.00 and set a “sector outperform” rating for the company in a research report on Friday, May 9th. Citigroup began coverage on shares of Arcellx in a report on Tuesday, June 17th. They set a “buy” rating and a $110.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $115.00 price objective on shares of Arcellx in a report on Monday, June 16th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $111.23.

Arcellx Stock Down 4.7%

NASDAQ:ACLX opened at $67.59 on Friday. Arcellx, Inc. has a twelve month low of $47.86 and a twelve month high of $107.37. The stock has a market cap of $3.72 billion, a P/E ratio of -22.61 and a beta of 0.28. The firm’s fifty day simple moving average is $64.75 and its 200 day simple moving average is $65.17.

Arcellx (NASDAQ:ACLX) last issued its earnings results on Thursday, May 8th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.29). Arcellx had a negative return on equity of 35.27% and a negative net margin of 211.46%. The business had revenue of $8.13 million during the quarter, compared to analysts’ expectations of $19.51 million. On average, analysts expect that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).